Results 261 to 270 of about 621,305 (415)

Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren, Moana Busch, Pedro A. Ruiz, Ermanno Malagola, Valeria Baumeler, Federica Foti, Adelina Gross, Tobias Grütter, Hendrik Edel, Cordelia Schuler, Kristina Handler, Glenn De Lange, Isabelle C. Arnold, Cheryl de Vallière, Klaus Seuwen, Martin Hausmann, Gerhard Rogler   +16 more
wiley   +1 more source

GISOAPP Onboarding Tool: Optimizing Onboarding for GI Surgical Oncology Advanced Practice Providers. [PDF]

J Adv Pract Oncol
Sullivan LT, Foley SB, Bazzell AF, Madsen LT.   +3 more
europepmc   +1 more source

Veterinary diagnostic imaging: probability, accuracy and impact [PDF]

Lamb, C R
core   +1 more source

Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: Revised staging criteria [PDF]

, 2017
Jacob A. Martin, Richard R.P. Warner, Juan P. Wisnivesky, Michelle Kang Kim   +3 more
openalex   +1 more source

TRPM8 levels determine tumor vulnerability to channel agonists

Molecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, Nicole Annesi, Sacha Genovesi, Annalisa Lorenzato, Karen Widmann, Michela Libergoli, Elisa Marmocchi, Giovanni Bertalot, Alberto Brolese, Mauro Giulio Papotti, Luca Molinaro, Orazio Caffo, Mattia Barbareschi, Alberto Bardelli, Alessandro Romanel, Sabrina Arena, Andrea Lunardi   +18 more
wiley   +1 more source

Developing a named entity framework for thyroid cancer staging and risk level classification using large language models. [PDF]

NPJ Digit Med
Fung MMH, Tang EHM, Wu T, Luk Y, Au ICH, Liu X, Lee VHF, Wong CK, Wei Z, Cheng WY, Tai ICY, Ho JWK, Wong JWH, Lang BHH, Leung KSM, Wong ZSY, Wu JT, Wong CKH.   +17 more
europepmc   +1 more source

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

Molecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte, Osheen Sharma, Laura Leuenberger, Emelie Wallin, Josefin Fernebro, Päivi Östling, Rebecka Bergström, Johan Lindberg, Ulrika Joneborg, Olli Kallioniemi, Brinton Seashore‐Ludlow   +10 more
wiley   +1 more source

A recent update on the morphological classification of intraductal papillary neoplasm of the bile duct: Correlation with postoperative prognosis and pathological features. [PDF]

PLoS One
Noguchi D, Kuriyama N, Kozuka Y, Komatubara H, Sakamoto T, Ito T, Hayasaki A, Iizawa Y, Fujii T, Tanemura A, Murata Y, Kishiwada M, Mizuno S.   +12 more
europepmc   +1 more source

Staging and reporting of urothelial carcinoma of the urinary bladder

Modern Pathology, 2009
Liang Cheng, R. Montironi, D. Davidson, A. López-Beltran   +3 more
semanticscholar   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source